Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The 25 of April is World Malaria Day - a good time to take stock of progress towards dealing with one of the great historical global scourges. Science blog by Kevin Marsh for the University of Oxford.

Insects flying

Malaria is caused by a tiny parasite transmitted to humans by the bite of certain sorts of (Anopheline) mosquitos. It occurs though the tropics and subtropics. Historically is has caused so many deaths that it has been one of the most powerful selective forces acting on human evolution.

At the turn of this century malaria was rightly described by many as a ‘disaster’: resistance to drugs used in treatment was widespread and estimates of deaths were in millions a year. There was a sense of national and international paralysis. In response to this dire situation came a whole set of initiatives, including declarations by heads of states the initiation of new public private partnerships and the launch of the Global Fund to fight AIDS, TB and malaria. Often such efforts are greeted with a certain amount of scepticism but in this case they marked the beginning of a log order rise in global investment in malaria control and a truly remarkable change in the global malaria situation.

Kevin MarshOver the next 15 years malaria reduced dramatically in almost all parts of the world accompanied by an incredible 60% reduction in malaria death rates. In large part this was due to the widespread deployment of effective new drugs, the so called artemisinin combinations and the use of bed nets impregnated with insecticide. Encouraged by the possibilities many began to call for a new campaign of global malaria eradication. Others were concerned that this was hubristic, given the biological and social complexity of malaria. The WHO set out in 2015 a Global Technical Strategy, which while disappointing some by not calling for eradication in any short time frame, was in fact very ambitious in aiming at a 90% reduction in malaria deaths by 2030 and at least 35 countries to have achieved elimination.

Over the last few years we have come to a more realistic and nuanced appreciation of the global position. In areas of lower transmission progress toward the elimination targets is on track but at the other end of the spectrum malaria remains a major cause of death in high burden countires. 75% of the worlds estimated 435,000 deaths each year occur in just 11 countries, ten of them in Africa and the eleventh being India. Here progress is in danger of stalling without concerted political and societal action. Against this background there is also concern about emerging drug and insecticide resitance and static levels of international funding. On the more optimistic side there is exciting progress towards potential new tools including drugs, vaccines and ways of genetically modifying mosquito populations.

So on malaria day 2019 we can reflect both on the massive progress over the last 19 years and but also on the considerable challenges ahead. It is a matter of pride that researchers from many parts of Oxford University and especially the major overseas collaborating programmes in south East Asia and Africa have played a central role in the many of the developments that have contributed to the progress described above.

This blog was published on the University of Oxford website

Similar stories

Tropical Medicine DPhil Students awarded NDM Prize

Every year, the Nuffield Department of Medicine awards NDM Prizes to our most outstanding students. This year, Mo yin and Rebecca Inglis (both at MORU) were highly commended in the category NDM Overall Prize, for conducting research with an outstanding impact. Will Schilling (MORU) received a prize as first year DPhil student, and Mohammad Ali (OCGHR) as second year DPhil student. Our warmest congratulations to you all!

New study alerts to the risk of poor quality medicines used to prevent and treat cardiovascular disease

There are important but neglected issues with substandard and falsified medicines and medical products used to prevent and treat cardiovascular diseases. From limited available data, MORU and IDDO scientists found about one fifth of medicines reported as sampled in the literature were substandard or falsified. This systematic review suggests that more and better quality data and data sharing are needed to better understand the global burden of this problem and inform interventions.

Systematic review identifies research gaps for Chagas disease

A new, large-scale systematic review published in PLOS Neglected Tropical Diseases has identified clear, significant research gaps in the diagnosis and treatment of Chagas disease. The paper also highlights significant differences in study design, diagnostic methods, duration of follow-up, and the timing of outcome assessment used by investigators even in the last decade.

The scale of the problem of visceral leishmaniasis in pregnancy is underestimated

Despite the limitations and paucity of data, the most comprehensive review of visceral leishmaniasis to date in pregnant women and vertical transmission of leishmaniasis has confirmed that liposomal amphotericin B is the safest treatment option and it is critical to ensure access to this.

RECOVERY Trial announced as overall winner of Best COVID-19 Response Project Award in the UK

The RECOVERY Trial has won the Project Management Institute’s Special Covid-19 UK Response Project Award. The award specifically recognised RECOVERY’s work to investigate whether the cheap steroid dexamethasone was an effective treatment for patients hospitalised with severe COVID-19.

ISARIC COVID-19 clinical database passes ½ million patient records mark

COVID-19 has exposed our vulnerability to pandemic infections and shown what works, and what does not. It has tested the effectiveness of the Oxford-based global, open-source, collaborative approach set up 10 years ago to prevent illness and deaths from infectious disease outbreaks: ISARIC, the International Severe Acute Respiratory and Emerging Infection Consortium.